Cancerous Inhibitor of PP2A (CIP2A) was first described as a fusion protein detected in a leukemia patient (17), which is an endogenous PP2A inhibitor that has been shown to have both proto-oncogenic and prognostic value in cancer. Here, PTPA is linked to cancer.